<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36242734</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1182</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Molecular neurobiology</Title><ISOAbbreviation>Mol Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Anti-apoptotic Splicing Variant of AIMP2 Recover Mutant SOD1-Induced Neuronal Cell Death.</ArticleTitle><Pagination><StartPage>145</StartPage><EndPage>159</EndPage><MedlinePgn>145-159</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12035-022-03073-1</ELocationID><Abstract><AbstractText>Although a couple of studies have reported that mutant superoxide dismutase 1 (SOD1), one of the causative genes of familial amyotrophic lateral, interacts physically with lysyl-tRNA synthetase (KARS1) by a gain of function, there is limited evidence regarding the detailed mechanism about how the interaction leads to neuronal cell death. Our results indicated that the aminoacyl-tRNA synthetase-interacting multi-functional protein 2 (AIMP2) mediated cell death upon the interplay between mutant SOD1 and KARS1 in ALS. Binding of mutant SOD1 with KARS1 led to the release of AIMP2 from its original binding partner KARS1, and the free form of AIMP2 induced TRAF2 degradation followed by TNF-&#x3b1;-induced cell death. We also suggest a therapeutic application that overexpression of DX2, the exon 2-deleted antagonistic splicing variant of AIMP2 (AIMP2-DX2), reduced neuronal cell death in the ALS mouse model. Expression of DX2 suppressed TRAF2 degradation and TNF-&#x3b1;-induced cell death by competing mode of action against full-length AIMP2. Motor neuron differentiated form iPSC showed a resistance in neuronal cell death after DX2 administration. Further, intrathecal administration of DX2-coding adeno-associated virus (AAV) improved locomotive activity and survival in a mutant SOD1-induced ALS mouse model. Taken together, these results indicated that DX2 could prolong life span and delay the ALS symptoms through compensation in neuronal inflammation.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kook</LastName><ForeName>Myung Geun</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul, 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Byun</LastName><ForeName>Mi Ran</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedicinal and Pharmaceutical Sciences, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Soo Min</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, College of Dentistry and Research Institute of Oral Science, Gangneung-Wonju National University, Gangwon-do, 25457, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Min Hak</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, College of Dentistry and Research Institute of Oral Science, Gangneung-Wonju National University, Gangwon-do, 25457, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dae Hoon</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, College of Dentistry and Research Institute of Oral Science, Gangneung-Wonju National University, Gangwon-do, 25457, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyung Been</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Dentistry and Research Institute of Oral Science, Gangneung-Wonju National University, Gangwon-do, 25457, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eui-Jin</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, College of Dentistry and Research Institute of Oral Science, Gangneung-Wonju National University, Gangwon-do, 25457, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>Kyunghwa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedicinal and Pharmaceutical Sciences, Kyung Hee University, Seoul, 02447, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Generoath Ltd, Seoul, 04168, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sunghoon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicinal Bioconvergence Research Center, Institute for Artificial Intelligence and Biomedical Research, College of Pharmacy and College of Medicine, Gangnam Severance Hospital, Yonsei University, Incheon, 21983, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Kyung-Sun</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, 08826, Republic of Korea. kangpub@snu.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul, 08826, Republic of Korea. kangpub@snu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jin Woo</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0003-1177-598X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology, College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea. jinwoo.ch@khu.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, College of Dentistry and Research Institute of Oral Science, Gangneung-Wonju National University, Gangwon-do, 25457, Republic of Korea. jinwoo.ch@khu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NRF-2017R1A5A2014768</GrantID><Agency>Ministry of Science and ICT of Korea</Agency><Country/></Grant><Grant><GrantID>NRF-2018R1A2B3008483</GrantID><Agency>Ministry of Science and ICT of Korea</Agency><Country/></Grant><Grant><GrantID>2019R1A2C1006752</GrantID><Agency>Ministry of Science and ICT of Korea</Agency><Country/></Grant><Grant><GrantID>NRF-2021R1A3B1076605</GrantID><Agency>Ministry of Science and ICT of Korea</Agency><Country/></Grant><Grant><GrantID>NRF-2016M3A6A4929906</GrantID><Agency>Ministry of Science and ICT of Korea</Agency><Country/></Grant><Grant><GrantID>NRF-2022R1A2C2009281</GrantID><Agency>Ministry of Science and ICT of Korea</Agency><Country/></Grant><Grant><GrantID>2020-22-0358</GrantID><Agency>Yonsei University</Agency><Country/></Grant><Grant><GrantID>2020-22-0356</GrantID><Agency>Yonsei University</Agency><Country/></Grant><Grant><GrantID>2021-22-0061</GrantID><Agency>Yonsei University</Agency><Country/></Grant><Grant><GrantID>21153MFDS601</GrantID><Agency>Ministry of Food and Drug Safety of Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Neurobiol</MedlineTA><NlmUniqueID>8900963</NlmUniqueID><ISSNLinking>0893-7648</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047992">TNF Receptor-Associated Factor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="Y">Nuclear Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047992" MajorTopicYN="N">TNF Receptor-Associated Factor 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AIMP2</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">DX2</Keyword><Keyword MajorTopicYN="N">KARS1</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">TRAF2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>15</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36242734</ArticleId><ArticleId IdType="doi">10.1007/s12035-022-03073-1</ArticleId><ArticleId IdType="pii">10.1007/s12035-022-03073-1</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9(11):617&#x2013;628. https://doi.org/10.1038/nrneurol.2013.203</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH (2017) Amyotrophic lateral sclerosis. Lancet 390(10107):2084&#x2013;2098. https://doi.org/10.1016/S0140-6736(17)31287-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Bender DE, Segal BM, Feldman EL (2015) The dual roles of immunity in ALS: injury overrides protection. Neurobiol Dis 77:1&#x2013;12. https://doi.org/10.1016/j.nbd.2015.02.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.02.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P, Brown RH (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7(9):710&#x2013;723. https://doi.org/10.1038/nrn1971</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1971</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucchia M, Ramirez A, Parente V, Simone C, Nizzardo M, Magri F, Dametti S, Corti S (2015) Therapeutic development in amyotrophic lateral sclerosis. Clin Ther 37(3):668&#x2013;680. https://doi.org/10.1016/j.clinthera.2014.12.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2014.12.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH (2001) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). The Cochrane database of systematic reviews (4):CD001447. https://doi.org/10.1002/14651858.CD001447</Citation></Reference><Reference><Citation>Rothstein JD (2017) Edaravone: a new drug approved for ALS. Cell 171(4):725&#x2013;726. https://doi.org/10.1016/j.cell.2017.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunn JS, Sakowski SA, Feldman EL (2014) Concise review: stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. Stem cells 32(5):1099&#x2013;1109. https://doi.org/10.1002/stem.1628</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.1628</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505&#x2013;512. https://doi.org/10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez A, Palomo Ruiz MD, Perez DI, Gil C (2017) Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Expert Opin Investig Drugs 26(4):403&#x2013;414. https://doi.org/10.1080/13543784.2017.1302426</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2017.1302426</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi S, Cova E, Davin A, Guareschi S, Abel K, Alvisi E, Laforenza U, Ghidoni R, et al (2010) SOD1 mRNA expression in sporadic amyotrophic lateral sclerosis. Neurobiol Dis 39(2):198&#x2013;203. https://doi.org/10.1016/j.nbd.2010.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.04.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J, Quick A, Kolb SJ (2017) Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med 19(3):267&#x2013;274. https://doi.org/10.1038/gim.2016.107</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2016.107</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen MJ, Lacroix JJ, Ramachandran S, Capone R, Whitlock JL, Ghadge GD, Arnsdorf MF, Roos RP, et al (2012) Mutant SOD1 forms ion channel: implications for ALS pathophysiology. Neurobiol Dis 45(3):831&#x2013;838. https://doi.org/10.1016/j.nbd.2011.08.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.08.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Abdel-Moaty H, Hunter J, Mhatre M, Mou S, Nguyen K, Potapova T, Pye QN, et al (2006) Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. J Neuroinflammation 3:2. https://doi.org/10.1186/1742-2094-3-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-3-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowing G, Dequen F, Soucy G, Julien JP (2006) Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J Neurosci 26(44):11397&#x2013;11402. https://doi.org/10.1523/JNEUROSCI.0602-06.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0602-06.2006</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S, Kiaei M, Wille E, Calingasan NY, Flint Beal M (2006) Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice. J Neurol Sci 251(1&#x2013;2):44&#x2013;49. https://doi.org/10.1016/j.jns.2006.08.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2006.08.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Fedynyshyn J, Ferrell S, Floyd RA, Gordon B, Grammas P, Hamdheydari L, Mhatre M, et al (2003) Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis 14(1):74&#x2013;80. https://doi.org/10.1016/s0969-9961(03)00087-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0969-9961(03)00087-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Pare B, Lehmann M, Beaudin M, Nordstrom U, Saikali S, Julien JP, Gilthorpe JD, Marklund SL, et al (2018) Misfolded SOD1 pathology in sporadic amyotrophic lateral sclerosis. Sci Rep 8(1):14223. https://doi.org/10.1038/s41598-018-31773-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31773-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch C, O&#x2019;Brien J, Bertolotti A (2011) Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci USA 108(9):3548&#x2013;3553. https://doi.org/10.1073/pnas.1017275108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1017275108</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Vande Velde C, Cleveland DW (2006) ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52(1):39&#x2013;59. https://doi.org/10.1016/j.neuron.2006.09.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.09.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur SJ, McKeown SR, Rashid S (2016) Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis. Gene 577(2):109&#x2013;118. https://doi.org/10.1016/j.gene.2015.11.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.11.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccon RA, Bunton-Stasyshyn RK, Fisher EM, Fratta P (2013) Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 136(Pt 8):2342&#x2013;2358. https://doi.org/10.1093/brain/awt097</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunst CB, Mezey E, Brownstein MJ, Patterson D (1997) Mutations in SOD1 associated with amyotrophic lateral sclerosis cause novel protein interactions. Nat Genet 15(1):91&#x2013;94. https://doi.org/10.1038/ng0197-91</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0197-91</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SW, Cho BH, Park SG, Kim S (2004) Aminoacyl-tRNA synthetase complexes: beyond translation. J Cell Sci 117(Pt 17):3725&#x2013;3734. https://doi.org/10.1242/jcs.01342</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.01342</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SG, Ewalt KL, Kim S (2005) Functional expansion of aminoacyl-tRNA synthetases and their interacting factors: new perspectives on housekeepers. Trends Biochem Sci 30(10):569&#x2013;574. https://doi.org/10.1016/j.tibs.2005.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2005.08.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DG, Choi JW, Lee JY, Kim H, Oh YS, Lee JW, Tak YK, Song JM, et al (2012) Interaction of two translational components, lysyl-tRNA synthetase and p40/37LRP, in plasma membrane promotes laminin-dependent cell migration. FASEB J 26(10):4142&#x2013;4159. https://doi.org/10.1096/fj.12-207639</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.12-207639</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DG, Lee JY, Kwon NH, Fang P, Zhang Q, Wang J, Young NL, Guo M, et al (2014) Chemical inhibition of prometastatic lysyl-tRNA synthetase-laminin receptor interaction. Nat Chem Biol 10(1):29&#x2013;34. https://doi.org/10.1038/nchembio.1381</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1381</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YN, Nechushtan H, Figov N, Razin E (2004) The function of lysyl-tRNA synthetase and Ap4A as signaling regulators of MITF activity in FcepsilonRI-activated mast cells. Immunity 20(2):145&#x2013;151. https://doi.org/10.1016/s1074-7613(04)00020-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1074-7613(04)00020-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Hei Z, Wu S, Liu Z, Wang J, Fang P (2019) Retractile lysyl-tRNA synthetase-AIMP2 assembly in the human multi-aminoacyl-tRNA synthetase complex. J Biol Chem 294(13):4775&#x2013;4783. https://doi.org/10.1074/jbc.RA118.006356</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.006356</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JM, Park BJ, Park SG, Oh YS, Choi SJ, Lee SW, Hwang SK, Chang SH, et al (2008) AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53. Proc Natl Acad Sci USA 105(32):11206&#x2013;11211. https://doi.org/10.1073/pnas.0800297105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0800297105</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HS, Kim DG, Oh YS, Kwon NH, Lee JY, Kim D, Park SH, Song JH, et al (2013) Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression. Biochem J 454(3):411&#x2013;416. https://doi.org/10.1042/BJ20130550</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20130550</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JW, Kim DG, Park MC, Um JY, Han JM, Park SG, Choi EC, Kim S (2009) AIMP2 promotes TNFalpha-dependent apoptosis via ubiquitin-mediated degradation of TRAF2. J Cell Sci 122(Pt 15):2710&#x2013;2715. https://doi.org/10.1242/jcs.049767</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.049767</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JW, Um JY, Kundu JK, Surh YJ, Kim S (2009) Multidirectional tumor-suppressive activity of AIMP2/p38 and the enhanced susceptibility of AIMP2 heterozygous mice to carcinogenesis. Carcinogenesis 30(9):1638&#x2013;1644. https://doi.org/10.1093/carcin/bgp170</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgp170</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JW, Kim DG, Lee AE, Kim HR, Lee JY, Kwon NH, Shin YK, Hwang SK, et al (2011) Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis. PLoS Genet 7(3):e1001351. https://doi.org/10.1371/journal.pgen.1001351</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1001351</ArticleId></ArticleIdList></Reference><Reference><Citation>Raoul C, Buhler E, Sadeghi C, Jacquier A, Aebischer P, Pettmann B, Henderson CE, Haase G (2006) Chronic activation in presymptomatic amyotrophic lateral sclerosis (ALS) mice of a feedback loop involving Fas, Daxx, and FasL. Proc Natl Acad Sci USA 103(15):6007&#x2013;6012. https://doi.org/10.1073/pnas.0508774103</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0508774103</ArticleId></ArticleIdList></Reference><Reference><Citation>Beier CP, Wischhusen J, Gleichmann M, Gerhardt E, Pekanovic A, Krueger A, Taylor V, Suter U, et al (2005) FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. J Neurosci 25(29):6765&#x2013;6774. https://doi.org/10.1523/JNEUROSCI.1700-05.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1700-05.2005</ArticleId></ArticleIdList></Reference><Reference><Citation>Aebischer J, Bernard-Marissal N, Pettmann B, Raoul C (2013) Death receptors in the selective degeneration of motoneurons in amyotrophic lateral sclerosis. J Neurodegener Dis 2013:746845. https://doi.org/10.1155/2013/746845</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/746845</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortarolo M, Lo Coco D, Veglianese P, Vallarola A, Giordana MT, Marcon G, Beghi E, Poloni M, et al (2017) Amyotrophic lateral sclerosis, a multisystem pathology: insights into the role of TNFalpha. Mediators Inflamm 2017:2985051. https://doi.org/10.1155/2017/2985051</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/2985051</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidotti G, Scarlata C, Brambilla L, Rossi D (2021) Tumor necrosis factor alpha in amyotrophic lateral sclerosis: friend or foe? Cells 10(3). https://doi.org/10.3390/cells10030518</Citation></Reference><Reference><Citation>Brohawn DG, O&#x2019;Brien LC, Bennett JP Jr (2016) RNAseq analyses identify tumor necrosis factor-mediated inflammation as a major abnormality in ALS spinal cord. PLoS ONE 11(8):e0160520. https://doi.org/10.1371/journal.pone.0160520</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0160520</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz M, Hottinger A, Paterna JC, Zurn AD, Aebischer P, Bueler H (2000) Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2. Hum Mol Genet 9(5):803&#x2013;811. https://doi.org/10.1093/hmg/9.5.803</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/9.5.803</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz CK, Federici T, Yang J, Backus C, Oh SS, Teng Q, Carlton E, Bishop KM, et al (2009) Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol Dis 33(3):473&#x2013;481. https://doi.org/10.1016/j.nbd.2008.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.12.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez BA, Shutterly A, Chan YK, Byrne BJ, Corti M (2020) Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci 10(2). https://doi.org/10.3390/brainsci10020119</Citation></Reference><Reference><Citation>Ratushny V, Golemis E (2008) Resolving the network of cell signaling pathways using the evolving yeast two-hybrid system. Biotechniques 44(5):655&#x2013;662. https://doi.org/10.2144/000112797</Citation><ArticleIdList><ArticleId IdType="doi">10.2144/000112797</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoroso MW, Croft GF, Williams DJ, O&#x2019;Keeffe S, Carrasco MA, Davis AR, Roybon L, Oakley DH, et al (2013) Accelerated high-yield generation of limb-innervating motor neurons from human stem cells. J Neurosci 33(2):574&#x2013;586. https://doi.org/10.1523/JNEUROSCI.0906-12.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0906-12.2013</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods 9(4):357&#x2013;359. https://doi.org/10.1038/nmeth.1923</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1923</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan AR, Hall IM (2010) BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26(6):841&#x2013;842. https://doi.org/10.1093/bioinformatics/btq033</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq033</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10):R80. https://doi.org/10.1186/gb-2004-5-10-r80</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2004-5-10-r80</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Kamaruzaman NA, Fung JN, Taylor SM, Turner BJ, Atkin JD, Woodruff TM, Noakes PG (2013) Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neuroinflammation 10:119. https://doi.org/10.1186/1742-2094-10-119</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-10-119</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F (2017) Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol 8:1005. https://doi.org/10.3389/fimmu.2017.01005</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId></ArticleIdList></Reference><Reference><Citation>Geloso MC, Corvino V, Marchese E, Serrano A, Michetti F, D&#x2019;Ambrosi N (2017) The dual role of microglia in ALS: mechanisms and therapeutic approaches. Front Aging Neurosci 9:242. https://doi.org/10.3389/fnagi.2017.00242</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00242</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JW, Lee JW, Kim JK, Jeon HK, Choi JJ, Kim DG, Kim BG, Nam DH, et al (2012) Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer. J Mol Cell Biol 4(3):164&#x2013;173. https://doi.org/10.1093/jmcb/mjs018</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjs018</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnerbauer M, Wheeler MA, Quintana FJ (2020) Astrocyte crosstalk in CNS inflammation. Neuron 108(4):608&#x2013;622. https://doi.org/10.1016/j.neuron.2020.08.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ban J, Samano C, Mladinic M, Munitic I (2019) Glia in amyotrophic lateral sclerosis and spinal cord injury: common therapeutic targets. Croat Med J 60(2):109&#x2013;120. https://doi.org/10.3325/cmj.2019.60.109</Citation><ArticleIdList><ArticleId IdType="doi">10.3325/cmj.2019.60.109</ArticleId></ArticleIdList></Reference><Reference><Citation>Voet S, Prinz M, van Loo G (2019) Microglia in central nervous system inflammation and multiple sclerosis pathology. Trends Mol Med 25(2):112&#x2013;123. https://doi.org/10.1016/j.molmed.2018.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2018.11.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni F, Quintana FJ (2020) The role of astrocytes in CNS inflammation. Trends Immunol 41(9):805&#x2013;819. https://doi.org/10.1016/j.it.2020.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2020.07.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata H, Magrane J, Kunst C, King MP, Manfredi G (2008) Lysyl-tRNA synthetase is a target for mutant SOD1 toxicity in mitochondria. J Biol Chem 283(42):28321&#x2013;28328. https://doi.org/10.1074/jbc.M805599200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M805599200</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Karuppagounder SS, Shin JH, Lee YI, Ko HS, Swing D, Jiang H, Kang SU, et al (2013) Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci 16(10):1392&#x2013;1400. https://doi.org/10.1038/nn.3500</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3500</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Yang Y, Ashwell JD (2002) TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416(6878):345&#x2013;347. https://doi.org/10.1038/416345a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/416345a</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Zhang J, Zhang Y, Wang Z, Song Y, Wei S, He M, You S, et al (2019) TRAF2 protects against cerebral ischemia-induced brain injury by suppressing necroptosis. Cell Death Dis 10(5):328. https://doi.org/10.1038/s41419-019-1558-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1558-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda C, Baiocchi C, Bongioanni P, Cova E, Guareschi S, Metelli MR, Rossi B, Sbalsi I, et al (2008) TNF and sTNFR1/2 plasma levels in ALS patients. J Neuroimmunol 194(1&#x2013;2):123&#x2013;131. https://doi.org/10.1016/j.jneuroim.2007.10.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2007.10.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J, Calingasan NY, Schafer P, et al (2006) Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 26(9):2467&#x2013;2473. https://doi.org/10.1523/JNEUROSCI.5253-05.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5253-05.2006</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbaric I, Miller G, Dear TN (2007) Appearances can be deceiving: phenotypes of knockout mice. Brief Funct Genomic Proteomic 6(2):91&#x2013;103. https://doi.org/10.1093/bfgp/elm008</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bfgp/elm008</ArticleId></ArticleIdList></Reference><Reference><Citation>Toder V, Fein A, Carp H, Torchinsky A (2003) TNF-alpha in pregnancy loss and embryo maldevelopment: a mediator of detrimental stimuli or a protector of the fetoplacental unit? J Assist Reprod Genet 20(2):73&#x2013;81. https://doi.org/10.1023/a:1021740108284</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1021740108284</ArticleId></ArticleIdList></Reference><Reference><Citation>Green DR, Llambi F (2015) Cell death signaling. Cold Spring Harb Perspect Biol 7(12). https://doi.org/10.1101/cshperspect.a006080</Citation></Reference><Reference><Citation>Palomeque J, Chemaly ER, Colosi P, Wellman JA, Zhou S, Del Monte F, Hajjar RJ (2007) Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther 14(13):989&#x2013;997. https://doi.org/10.1038/sj.gt.3302895</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gt.3302895</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>